Patent ID: 9737531
Date: 2017-08-22
CPC Classifications: A61K,A61P

Claim:
1. A composition for treating depression or psychosis with reduced akathisia side effects in a human in need of such treatment consisting essentially of: an akathisia-producing effective amount of a first compound consisting of a selective 5-HT2A receptor antagonist/inverse agonist selected from the group consisting of eplivanserin (SR46.349) and pimavanserin (ACP-103); and an effective amount of a second compound consisting of a selective NMDAR receptor antagonist, selected from the group consisting of D-CPPene and gavestinel, wherein the composition is formulated as a tablet or capsule for systemic oral administration, wherein the selective NMDAR receptor antagonist is a full NMDAR receptor antagonist; wherein the effective amount of the selective NMDAR receptor antagonist is sufficient to inhibit the akathisia-producing side effects of the first compound; and wherein the NMDAR receptor antagonist binds to at least one of the glycine or glutamate binding sites.